and pulmonary hemodynamics in a model of acute lung injury, but only d-Pro blocked the protection from lung edema and protein leak, whereas A779 restored the infiltration of neutrophils indicating that Ang-(1-7) may act via distinct receptors. 9 Therefore, we aimed to identify and quantify a second messenger stimulated by Ang-(1-7) allowing pharmacological confirmation of Mas as a functional heptapeptide receptor, to understand the postulated interaction between AT2 and Ang-(1-7), and to discover the hypothetical second receptor, by working with primary and receptor-transfected cells and in vivo approaches.
Methods
Most of the techniques have been previously described in detail by our group, including culture of primary cells 10 and culture and transfection of human embryonic kidney (HEK293) cells. 11 A detailed description of techniques, where there is no reference by our group, is provided in full detail including cAMP measurement, quantification of protein kinase A (PKA) activity and cAMP response element-binding (CREB) phosphorylation, and measurement of acute hemodynamic effects.
Mice deficient in Mas and MrgD (double knockout) have been generated through breeding of single Mas 12 and MrgD 13 (strain no. 36050, B6.129S1-Mrgprd tm5Mjz /Mmnc; The Mutant Mouse Regional Resource Center 8U42OD010924-13, Chapel Hill, NC) knockouts in the animal facilities at University College Cork (UCC), Ireland.
Chemicals and Reagents
Ang-(1-7), d-Ala7-Ang-(1-7), d-Pro7-Ang- (1) (2) (3) (4) (5) (6) (7) were from Biosynthan (Berlin, Germany). Adrenaline, forskolin, HOE 140 (icatibant), 3-isobutyl-1-methylxanthine (IBMX), isoproterenol, RPMI1640, trypsin/EDTA, phenylmethylsulfonyl fluoride (PMSF), protease inhibitor cocktail, and phosphatase inhibitor cocktail were purchased from Sigma Aldrich (St. Louise, MO). DMEM was purchased from BioScience (Dun Laoghaire, Dublin, Ireland). Fetal bovine serum was purchased from GIBCO (Life Technologies, Carlsbad, CA). N ω -Nitro-l-arginine methyl ester hydrochloride (l-NAME) was from Cayman Chemical Company (Ann Arbor, MI). PD123319 was from Parke-Davis Pharmaceutical Research (Detroit, MI). Transfection reagent was purchased from Qiagen (Venlo, Limburg, The Netherlands).
Cell Culture Conditions, Transfection, and Stimulation
HEK293 cells were cultured in DMEM medium supplemented with fetal bovine serum (10%), HEPES buffer (1%), sodium pyruvate (1%), and l-glutamine (1%) and maintained under standard conditions (5% CO 2 , 95% humidity, and 37°C). Cells were cultured in 75-cm 2 tissue culture flasks and seeded in 48-well plates at density of 75 000 cells per well. The next day, HEK293 cells were transfected using transient transfection procedure after manufacturer's instructions. Briefly, 150 ng of pcDNA3.1 or a combination of 50 ng of pcDNA3.1 and 100 ng of Mas, MrgD, AT2, or Mrg 11 were mixed with serum-free medium and PolyFect transfection reagent. After 10 minutes, incubation at room temperature which allowed the complex formation, the medium containing serum and other supplements was added, and the total volume was transferred into appropriate wells of 48-well plates. The cells were incubated for 16 to 20 hours. The next day, the medium was replaced by serum-free medium 1 hour before stimulation. After stimulated with A779, dPro, IBMX, HOE 140, l-NAME, PD123319, forskolin, or IBMX (all 10 -6 M) for 10 minutes, the solvent, Ang-(1-7) or isoproterenol (all 10 −7 M) were added for 15 minutes. Then, the cells were lysed by adding 180 μL/well 0.1 N hydrochloric acid with 0.1% Triton X-100, and the lysates were stored at −80°C until further use. The protein concentration was determined using Pierce BCA Protein Assay Kit according to the manufacturer's protocol (Thermo Fisher Scientific, Waltham, MA).
Isolation and Culture of Primary Cells and Their Stimulation
Primary aortic vascular smooth muscle cells (VSMCs) were isolated from the thoracic aortas of 6-to 8-week-old male C57/BL6 mice and cultured as described previously. 10 Kidney mesangial cells (MCs) were isolated from 10-to 12-week-old female mice deficient in Mas, 12 
MrgD
13 (strain no. 36050, B6.129S1-Mrgprd tm5Mjz /Mmnc, The Mutant Mouse Regional Resource Center 8U42OD010924-13, MMRRC, Chapel Hill, NC), or in both (generated through cross-breeding of both single knocks in the animal facilities at UCC, Cork, Ireland) and from their age-and sex-matched C57/BL6 control according to the protocol previously described. 10 VSMC were used between passage 2 and 3, whereas MC were used at passage 2. Cardiac fibroblasts were isolated from ventricles of adult male C57/BL6 mice as described previously.
14 Primary human dermal microvascular endothelial cells were purchased from European Collection of Cell Cultures (Salisbury, United Kingdom). Primary human umbilical vein endothelial cells (HUVEC) were purchased from LONZA BioResearch (Basel, Switzerland). Mouse endothelial cells from cerebral cortex, bEnd.3, were a gift from Dr Siems from FMP (Forschungsinstitut fuer Molekulare Pharmakologie, Berlin, Germany). All primary cells were cultured in 75-cm 2 tissue culture flasks and seeded for cAMP assay in 24-well plates at density of 75 000 cells per well. For protein isolation, cells where cultured in 50-mm dishes until 80% confluence. The stimulation with Ang-(1-7) or blockers was carried out as described above. For the test of the adenylyl cyclase (AC) inhibitor (SQ22536), cells were prestimulated with 2×10 −6 M for 15 minutes, followed by stimulation with Ang-(1-7) at 10 −7 M for 15 minutes.
Measurement of cAMP in Cell Lysates
cAMP concentration in cell lysates was determined using Direct cAMP ELISA kit (Enzo Life Sciences Ltd, Exeter, United Kingdom). Briefly, wells of 96-well plate (goat anti-rabbit IgG precoated) were neutralized with 50 μL of Neutralizing Reagent. Next, 100 μL of acetylated cAMP standard or cell lysate was added, followed by 50 μL of blue cAMP-alkaline phosphatase conjugate and 50 μL of yellow enzyme immunoassay rabbit anti-cAMP antibody. The plate was then incubated on a shaker (≈ 400 rpm) at room temperature for 2 hours. Next, the wells were aspirated and rinsed 3× with wash buffer (1:10, tris-buffered saline containing detergents and sodium azide in deionized water). After the final wash, the plate was tapped against clean paper towel to remove any remaining wash buffer. To each well, 200 μL of p-nitrophenyl phosphate substrate solution was added, and the plate was incubated for 1 hour at room temperature. The enzymatic reaction was stopped by adding 50 μL of stop solution, and the absorbance at 405 nm was measured immediately. The cAMP concentration was determined from nonlinear standard curve using GraphPad Prism 5.0 software.
Western Blot Analyses
Cells were lysed in radioimmunoprecipitation assay buffer buffer containing protease and phosphatase inhibitor cocktails (Sigma, St. Louis, MO M for 15 minutes. Cells were lysed in 50 μL (HEK293) or 100 μL (HUVEC) of activated cell lysis buffer provided by the kit, containing 1 mmol/L PMSF, 1 μL/mL protease and phosphatase inhibitor cocktail (Sigma) and incubated for 30 minutes on ice. The lysates were transferred to 1.5 mL reaction tubes and centrifuged at 10 000 rpm at 4°C for 10 minutes. The supernatant was directly used for analysis or stored at −80°C till measurement. For measurement, all samples were diluted 1:10 in kinase assay buffer provided by the Kit. For the measurement, 40 μL of the sample (in triplicates) or standard (in duplicates) were pipetted in to each well. Afterward, 10 μL of ATP was added to each well and incubated for 1.5 hours at 30°C on a shaker. Next, the wells were aspirated and rinsed 4× with wash buffer (1:20 in deionized water). After the final wash, the plate was tapped against clean paper towel to remove any remaining wash buffer. Twenty-five microlitre of the goat anti-rabbit IgG horseradish peroxidase and 25 μL of the rabbit phospho PKA substrate antibody were added to each well and incubated at room temperature for 60 minutes with shaking. The wells were aspirated again and rinsed 4× with wash buffer (1:20 in deionized water). After the final wash, the plate was tapped against clean paper towel to remove any remaining wash buffer. Next, 100 μL of the TMB substrate solution were added to each well and incubated for 30 minutes at room temperature. Afterward, 50 μL of stop solution was added to each well and the optical density was measured in a plate reader at 450 nm. The PKA activity (U/mL) was determined from linear standard curve using linear regression from Excel.
Dual-Luciferase Reporter Assay
For dual-luciferase reporter assays, HEK293 cells were seeded into 48-well plates (75 000 cells/well). About 24 hours later, cells were transiently transfected with 100 ng eukaryotic expression vectors of AT1 11 , AT2 or Mrg together with 25 ng pNFAT-TA-Luc-, (BD Biosciences, Heidelberg, Germany) or pELK-Luc Reporter Vector (Signosis, Santa Clara, CA) luciferase reporter plasmids and 25 ng pRL-TK (Promega GmbH, Mannheim, Germany) using the protocol described above. Next day, the medium was replaced by serum-free medium 1 hour before stimulation. After 6 hours of stimulation with Ang-(1-7) or Ang II (10 −7 M and 10 −6 M), cells were lysed with 65-μL/ well passive lysis buffer provided with the Dual Luciferase Reporter Assay kit (Promega GmbH) and incubated on a shaker for 15 minutes at room temperature. The activity for Firefly and Renilla Luciferase was measured with Orion L Microplate Luminometer (Berthold Detection Systems GmbH, Pforzheim, Germany) according to the manufactures protocol. Briefly, 30 μL of lysed cells were transferred into a white 96-MicroWell plate (Thermo Fisher Scientific), and 100 μL of luciferase assay reagent II was added. After quantifying the firefly luminescence, the reaction was quenched by adding 100 μL of Stop & Glo reagent, and renilla activity was measured. For calculations, the ratio of firefly and renilla luciferase was used.
mRNA Isolation and Real-Time PCR
Total cellular RNA was isolated using the NucleoSpin RNA Isolation Kit (MACHEREY-NAGEL, Düren, Germany) according to the manufacturer's protocol. After isolation, 2000 ng of total RNA was transcribed into cDNA using the RevertAid H Minus First Strand cDNA Synthesis kit (MBI Fermentas, Hanover, MD) and oligo(dT)18 primer. After synthesis, RNAse free water was added to the single cDNA to a final volume of 100 μL. Quantification of gene expression was performed by quantitative real-time polymerase chain reaction on the StepOne Real-Time PCR System (Thermo Fisher Scientific) using the Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) and specific primers: Mas forward: CCTCCCATTCTTCGAAGCTGTA, Mas reverse: GCCTGGGTTGC-ATTTCATCTTT, MrgD forward: TCTACTGGGTGGATGTGAAACG, MrgD reverse: TCATTAGTA CACGTGGATGGCG, AT2 forward: GAATTACCCGTGACCAA GTCCT, and AT2 reverse: GGAACTCTAAACACACTGCGGA. Quantitative real-time polymerase chain reaction amplifications were performed in a final volume of 20 μL at 95°C for 15 minutes followed by 40 cycles with denaturation at 95°C for 30 s, annealing at 58°C for 30 s and elongation at 72°C for 30 s. PCR products were finally subjected to a melting curve analysis. The mRNA levels were quantified with the StepOne analysis software in comparative quantitation mode and normalized to β-actin expression levels. All quantitative real-time polymerase chain reactions were done at least 3× using RNA from independent experiments.
Measurement of Arterial Pressure and Heart Rate
The acute mean arterial pressure response to Ang-(1-7) injection was measured by direct cannulation in anesthetized 10-to 14-week-old male mice of wild-type and MrgD-deficient genotype. 15 The mice were anesthetized with a combination of ketamine (107 mg/kg body weight) and xylacine (17.1 mg/kg body weight) given intraperitoneally. Body temperature was maintained at 37°C. The right caroid artery was cannulated with PE-10 tubing and connected to a physiological pressure transducer (MEMSCAP, Skoppum, Norway), and the mean arterial pressure was continuously recorded with a digital data recorder (Laboratory Chart, ADInstruments Ltd, Oxford, United Kingdom). The heart rate was recorded using mouse needle electrodes (AD Instruments Ltd). After stabilization, Ang-(1-7) (30 μg/ kg body weight) was injected in the tail vein. The mean arterial pressure and heart rate were monitored continuously for 30 minutes.
In Silico Modeling
The 3-dimensional structure of Ang-(1-7) was prepared by minimizing their nuclear magnetic resonance experimental structures (PDB:2JP8) with AMBER* force field and in water solvent using Schrödinger Macromodel (MacroModel, version 9.7, Schrödinger, LLC, New York, NY). It was further docked (keeping the backbone rigid) with Autodock 4.2.3 16 into a modeled structure of Mas receptor, 17 in which the F112 side chain conformation was modified to create a larger binding site and to expose specific binding residue. 18, 19 The complex was minimized as before. The resulting conformation of Ang-(1-7) was considered the bioactive conformation. Hercules software (Intelligent Pharma S.L., Barcelona, Spain) was applied to superpose PD123319 over Ang-(1-7). PD123319 nonring bonds were treated as flexible (amide bonds set to either 0° or 180°), whereas flexible ring conformations were computed with Corina (Corina_ Linux2 3.46, Molecular Networks GmbH, Erlangen, Germany) using an energy window value of 20 kJ/mol. Ionization states were estimated with Schrödinger Epik (Epik version 2.8017, Schrödinger, LLC, 2009, New York, NY), and Gasteiger charges were assigned to atoms in both molecules as implemented in Open babel.
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Statistical Analyses
Data presented are mean±SEM. Data were analyzed by Student t test or 1-way and 2-way ANOVA tests accompanied by Bonferroni post hoc test using GraphPad Prism 6.0 (GraphPad Software Inc, San Diego, CA). A P value of <0.05 was considered statistically significant. -(1-7) . Furthermore, Liu et al 22 described the stimulation of intracellular signaling by Ang-(1-7) in glomerular MCs. Their data indicated that the heptapeptide can increase intracellular cAMP. As we aimed to identify the receptors associated with Ang- (1-7) signaling, we initially examined whether cAMP would be an efficient readout to quantify changes in intracellular signaling after Ang-(1-7) stimulation. Ang-(1-7) increased cAMP in a dose-dependent manner in primary MCs with highest efficacy at 10 −7 M and a half-maximal effective concentration (EC 50 ) value of 6.2 nmol/L ( Figure  1A ). This increase was blocked by the 2 Ang-(1-7) antagonists, A779 and d-Pro, but also by the AT2 receptor blocker PD123319 ( Figure 1B) . As a variety of papers described the blocking effect of the bradykinin B 2 receptor blocker, icatibant, as well as the inhibitory effect of the NO synthase inhibitor l-NAME, on Ang-(1-7)-mediated signaling, 23 we tested both substances in our primary-cell assay. Although icatibant failed to block an Ang-(1-7)-mediated increase in cAMP, l-NAME inhibited the effects of Ang- (1-7) . The heptapeptide could not add to the increased concentration of cAMP reached by l-NAME treatment alone ( Figure 1B) .
To test the ability of Ang-(1-7) to increase cAMP in other cell types, we stimulated primary cardiac fibroblasts and VSMC with the heptapeptide. Although cardiac fibroblasts did not respond to Ang-(1-7) (Figure 1C) , it increased cAMP in VSMC, and the same compounds blocked the effect as described for primary MCs ( Figure 1D ).
Ang-(1-7) Stimulates the Generation of Intracellular cAMP in Endothelial Cells
Because Ang-(1-7) relaxes vessels in an endotheliumdependent manner, 24 we tested the most commonly used endothelial cell-line, HUVECs, for its response to Ang-(1-7). As described before for other cell-lines, the peptidemediated increase in intracellular cAMP could be blocked by A779, d-Pro, PD123319, and inhibited by l-NAME ( Figure 2A ). As shown in Figure 2B , the increase in cAMP was concentration dependent, whereby the EC 50 was reached at 13 nmol/L. Because the concentration of cAMP depends on its generation as well as its degradation, we tested whether the Ang-(1-7)-mediated raise in cAMP is the consequence of increased stimulation of AC or decreased activity of phosphodiesterases. We used Forskolin, an activator of AC, which directly stimulates cAMP level and IBMX, a nonselective phosphodiesterase inhibitor, which inhibits cAMP degradation. As expected, both Forskolin and IBMX led to an increase in intracellular cAMP ( Figure 2C ). However, Ang-(1-7) could increase cAMP levels stimulated by IBMX but did not further increase the levels reached by Forskolin alone. The additive effect of Ang-(1-7) and IBMX excludes the Ang-(1-7)-mediated raise in cAMP to be a result of phosphodiesterase inhibition.
To finally confirm that Ang-(1-7)-mediated increase in cAMP is AC dependent, we used the specific enzyme inhibitor SQ22536. As shown in Figure 2D , the SQ22536 alone had no effect on cAMP concentration but the inhibitor blunted the Ang-(1-7)-mediated raise in cAMP linking Ang- (1-7) signaling to G αs /AC/cAMP axis.
Because cAMP initiates a variety of downstream signaling pathways including PKA activation, we tested whether the Ang-(1-7)-mediated increase in cAMP leads to an increased PKA activity. Stimulation of HUVEC with Ang-(1-7) for 15 minutes resulted in a significant increase in PKA activity ( Figure 2E ).
Ang-(1-7) Stimulates the Generation of Intracellular cAMP in HEK293 Cells Expressing Either Mas or MrgD
To test for receptors involved in the Ang-(1-7)-mediated increase in cAMP levels, we used HEK293 cells. First, we tested untransfected cells to exclude that these cells already respond to the heptapeptide. As shown in the left panel of Figure 3A , the heptapeptide had no effect on cAMP levels, confirming HEK293 cells as an ideal tool to measure cAMP in response to Ang-(1-7) in receptor-transfected cells.
We chose 4 different receptors for further tests. First, we tested Mas as Ang-(1-7) has previously shown to be an endogenous ligand for this receptor. 6 Second, Mrg and MrgD receptors 11 Finally, we also tested the AT2 receptor because PD123319 is thought to be a specific AT2 receptor blocker, and we showed that it blocks the Ang-(1-7)-mediated increase in cAMP ( Figures  1B and 1D and 2A) . When HEK293 cells were transfected with plasmids for those 4 receptors, Ang-(1-7) stimulation caused a significant increase in intracellular cAMP levels in cells overexpressing Mas or MrgD but not Mrg and AT2 ( Figure 3A, right) .
To exclude other main signaling pathways for AT2 and Mrg to be activated by Ang- (1-7) involving other G proteins such as G αq/11 and G αi , we tested activation of these 2 G proteins by measuring activation of transcription factors specifically activated by them. We have chosen nuclear factor for activated T cells, which is known to be coupled to G αq/11 11 and Elk1 as indicator for G αi activation. 25 Because AT1 receptor is known to signal through G αq/11 and G αi after stimulation with Ang II, 26 we used this receptor as the positive control. As expected, Ang II increased luciferase production in AT1 receptor expressing cells cotransfected with either nuclear factor for activated T cells or Elk1 ( Figure 3B and 3C, right). In contrast, Ang-(1-7) failed to stimulate any of the transcription factors in AT2-and Mrg-expressing HEK293 cells ( Figure 3B and 3C, left) . Notably, Ang-(1-7) has been also unable to stimulate the 2 G proteins in AT1-transfected cells.
We used both Mas and MrgD receptors to investigate in detail their involvement in Ang-(1-7)-mediated signaling. As shown in Figure 4A , Ang-(1-7) stimulation caused a dosedependent increase in the intracellular cAMP level in Mastransfected cells with an EC 50 of 5.5 nmol/L. Then, we selected the concentration of highest efficacy (10 −7 M) for further tests with the previously effective blockers. Figure 4B shows none of the 3 blockers had an effect on cAMP levels in pcDNA3.1-or Mas-transfected cells. However, the increase in cAMP concentration generated by Ang-(1-7) in Mas-transfected cells was blocked by all the 3 blockers ( Figure 4B) .
Independent experiments were performed on HEK293 cells transfected with MrgD, where Ang-(1-7) also caused a dose-dependent increase in cAMP concentration with an EC 50 value of 6.6 nmol/L ( Figure 4C ). In contrast to Mastransfected cells, only d-Pro and PD123319 blocked the Ang-(1-7)-mediated increase in cAMP level, whereas A779 had no significant effect ( Figure 4D ).
To confirm that the increase in PKA activity seen in HUVEC ( Figure 2E ) can be associated to Mas and MrgD signaling, we measured activity in response to Ang-(1-7) in Mas-and MrgDtransfected cells. In both receptor-overexpressing cells, the heptapeptide significantly increased PKA activity. This increase was blunted by the AC inhibitor SQ22536 ( Figure 4E ) confirming cAMP generation as the trigger for PKA activation. 
Ang-(1-7)-Mediated cAMP Generation Is Absent in MCs Derived From Mas/MrgD Knockout Animals
To confirm that Mas and MrgD are the 2 receptors used by Ang-(1-7) to generate cAMP in primary cells, we used MCs derived from double-knockout mice deficient in both receptors. These mice are fertile and without obvious morphological abnormalities. Initially, we examined whether the measured increase in cAMP in MCs is above the threshold to initiate downstream signaling ( Figure 1A ). Because one of the consequences of cAMP increase can be the activation of the transcription factor cAMP response element-binding protein (CREB), 27 we evaluated whether the Ang-(1-7)-mediated increase in cAMP can also induce CREB phosphorylation. Figure 5A and 5B shows that CREB phosphorylation occurred 5 minutes after Ang-(1-7) stimulation and reached control levels within 30 minutes. This induction was blunted by pretreatment with SQ22536 confirming cAMP generation as initial signal for CREB phosphorylation.
Next, we tested whether Ang-(1-7)-mediated increase in cAMP observed in wild-type MCs could be abolished in Masor MrgD-deficient cells or cells isolated from Mas/MrgD double knockouts. Deficiency in one of the receptors reduced the Ang-(1-7) signal generated in wild-type cells, whereas the double knockout completely blunted it ( Figure 5C ).
To exclude upregulation of the remaining receptor and also to confirm that both Mas and MrgD receptors are absent in knockout cells, we investigated the mRNA levels in MCs derived from double knockouts. Figure 5D shows that Mas and MrgD mRNA levels were barely detected in cells from double knockouts. Notably, deficiency in both receptors did not significantly alter AT2 mRNA levels.
Ang-(1-7)-Mediated Acute Hemodynamic Effects Are Blunted in MrgD-Deficient Mice
As we and others showed that vasorelaxant effects of Ang-(1-7) are Mas dependent, 8, 24 we finally tested whether the genetic deficiency in MrgD would also have an in vivo effect on the hemodynamic properties of Ang-(1-7). Acute bolus infusion of the heptapeptide led to a significant drop in mean arterial blood pressure, whereas no decrease was observed in MrgD knockouts ( Figure 5E ).
Discussion
The lack in knowing a second messenger for Ang-(1-7) prevented not only the pharmacological confirmation of assumed receptors and the identification of further hypothesized receptors but also the determination of efficacy and potency of a potential receptor/ligand interaction. The need of such second messenger is also illustrated by the fact that 2 publications during the past years intensively investigated phosphorylation of intracellular molecules 28 and quantities of intracellular proteins, 29 respectively, in response to Ang-(1-7). Although aimed to identify useful molecules for receptor pharmacology, the data published failed to add useful tools to this approach. Here, we demonstrate that a second messenger, cAMP, is an ideal tool to quantify changes in intracellular signaling mediated by Ang-(1-7). This allowed us to provide final pharmacological evidence that Mas is a functional receptor for Ang-(1-7). More importantly, the use of cAMP as a readout enabled us to screen for other receptors associated with Ang-(1-7) signaling in a hypothesis-based manner. Consequently, these results provide the first experimental proof that MrgD is a second receptor for Ang-(1-7) that has been confirmed under in vivo conditions. The hypothesis that MrgD acts as a receptor for the heptapeptide has been based on different findings including (1) high sequence homology between Mas and MrgD; (2) a description from a Brazilian group that Ala1-Ang-(1-7) but not Ang-(1-7) is a ligand for MrgD, 30 because unpublished modeling of both peptides excludes a decisive effect of the first amino acid on the G αs activation and thus made it likely that a receptor for Ala1-Ang-(1-7) is also a receptor for Ang-(1-7); and (3) our data that Ang-(1-7) can stimulate arachidonic acid release in MrgD-transfected cells. 11 However, the experiments with Mrg might seed doubts on the latter point, as the relatively moderate arachidonic acid release was not paralleled by an increase in cAMP in Mrg-transfected cells; but association between cAMP and arachidonic acid release warrants further investigation. We are the first group to establish cAMP as a readout for Ang-(1-7) receptor pharmacology, although there have been indications in the literature for such an association. Beside the work by Tallant and Clark 21 and by Liu et al 22 in primary cells, an article from 2012 showed indirect cAMP involvement in Ang-(1-7) signaling because its modulation of sympathetic activity in the paraventricular nucleus was abolished by an AC inhibitor and a PKA inhibitor. 31 Furthermore, physiological effects of the heptapeptide and effects in preclinical models also implicate the involvement of cAMP. For example, we demonstrated the dominant effect of Ang-(1-7) on hematopoietic stem cells/progenitors, 32 and there is a significant evidence that cAMP stimulates such processes. 33 Although Mas-deficient animals showed significant effects in preclinical models, they do not show a strong phenotype under physiological conditions 12 except endothelial dysfunction. 24 On the basis of our present data, one could argue that the lack in phenotype is a result of the heptapeptide's ability to shunt the lack of Mas by using the sequence and signaling-like receptor, MrgD. However, although not intensively phenotyped yet, the double knockouts look normal, are fertile, and show no increased mortality within 12 months. This further supports the hypothesis that Ang-(1-7) is effective especially under disease conditions. One of the key findings of this study is the exclusion of AT2 as a functional Ang-(1-7) receptor. Our experiments excluded not only activation of G αs by the heptapeptide in AT2-transfected cells and thus an increase in cAMP concentration but also coupling to 2 other major G proteins activated by G-protein-coupled receptors.
Furthermore, our data also provide the identification of the reason for the controversial discussion on Ang-(1-7)/ AT2 during the past years. There are only few published experiments using AT2 knockouts for the evaluation of an AT2-mediated part of Ang-(1-7) action showing either no effect or only partial effects. 34 However, there are many papers concluding that Ang-(1-7) acts via AT2, because of the blocking effect of PD123319. On the basis of our findings that PD123319 can also block Mas and MrgD, such a conclusion could be wrong as the blocking effect of PD123319 is not based on AT2 but on both Ang-(1-7) receptors.
This unspecific receptor profile of PD123319 might not be surprising, if we compare its structure with Ang-(1-7). PD123319 structure can be embedded in the molecular volume of the predicted bioactive conformation of Ang-(1-7) bound to Mas and displays chemical similarities to Ang-(1-7), implicating that both molecules fit into the 2 Ang-(1-7) receptors, whereby PD123319 may fail to stimulate intracellular signaling ( Figure 5F ).
However, identifying PD123319 as a nonspecific AT2 receptor blocker, also requires a careful re-evaluation of papers, which conclude that the effects blocked by PD123319 are mediated via AT2, as we now know that it could also relate to Mas and MrgD.
Taken together, our results correct the view on the reninangiotensin system (AT2 is not an Ang-(1-7) receptor), expand our understanding of the beneficial angiotensin-converting enzyme 2/Ang-(1-7)/Mas axis to a 2 receptor axis (Mas and MrgD), identify the primary intracellular signaling cascade for the heptapeptide when interacting with its receptors (G αs /AC/cAMP leading to an increase in PKA activity and CREB phosphorylation), and force a re-evaluation of >1000 publications concluding that effects blocked by PD123319 are AT2 specific.
Perspectives
As Ang-(1-7) has been identified as a protective peptide in cardiovascular diseases, the identification of a second receptor for the peptide allows for the development of tailored drugs (nonpeptidic agonists) stimulating either Mas or MrgD or both receptors depending on their expression/importance in diseases of different pathogenesis.
